Mathias Liljeblad
AstraZeneca R&D
Goeteborg, O, Sweden
Goeteborg, O, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Fibroblast activation protein and down-stream effects on its substrates in metabolic dysfunction-associated steatotic liver disease.
Journal: Scandinavian journal of gastroenterology
Published: June 03, 2026
Vascular endothelial growth factor A, a potential non-invasive biomarker for metabolic dysfunction-associated steatotic liver disease progression.
Journal: Clinical biochemistry
Published: September 09, 2024
AZD2693, a PNPLA3 antisense oligonucleotide, for the treatment of MASH in 148M homozygous participants: Two randomized phase I trials.
Journal: Journal of hepatology
Published: August 20, 2024
A Markov model of fibrosis development in nonalcoholic fatty liver disease predicts fibrosis progression in clinical cohorts.
Journal: CPT: pharmacometrics & systems pharmacology
Published: April 21, 2023
Hepatic patatin-like phospholipase domain-containing 3 levels are increased in I148M risk allele carriers and correlate with NAFLD in humans.
Journal: Hepatology communications
Published: February 10, 2022
Subcutaneous delivery of FGF21 mRNA therapy reverses obesity, insulin resistance, and hepatic steatosis in diet-induced obese mice.
Journal: Molecular therapy. Nucleic acids
Published: October 27, 2021
Review article: the emerging role of genetics in precision medicine for patients with non-alcoholic steatohepatitis.
Journal: Alimentary pharmacology & therapeutics
Published: December 13, 2019
Avidity-Based Affinity Enhancement Using Nanoliposome-Amplified SPR Sensing Enables Low Picomolar Detection of Biologically Active Neuregulin 1.
Journal: ACS sensors
Published: November 15, 2019
Thymosin Beta-4 Is Elevated in Women With Heart Failure With Preserved Ejection Fraction.
Journal: Journal of the American Heart Association
Published: June 15, 2017
Showing 1-9 of 9
Last Updated: 09/26/2026